REPROCELL

*Gameto Announces World’s First Live Birth Using Fertilo Procedure that Matures Eggs Outside the Body* Congratulations to the team at Gameto as they celebrate this achievement! Their procedure harnesses the power of REPROCELLs iPSCs, generated by the StemRNA Reprogramming Technology, to produce Fertilo ovarian support cells (OSCs). Fertilo provides a faster, safer, more accessible solution for families considering assisted reproduction technology (ART) such as in vitro fertilization (IVF) therapy. By maturing eggs outside the body and minimizing hormonal stimulation, Fertilo is improving outcomes and experiences for women utilizing ART. The result is a streamlined process that yields high-quality, mature eggs with similar efficacy to conventional IVF but in a fraction of the time and with potentially fewer complications. Find out more about this announcement: https://hubs.li/Q0309GfP0 Find out more about Gameto and Fertilo: https://hubs.li/Q0309Gr10 Find out more about REPROCELL's StemRNA Technology: https://hubs.li/Q0309C1-0

Looking for high-quality iPSCs to power your clinical research? At REPROCELL, we specialize in GMP-compliant iPSC production, offering unmatched quality, consistency, and scalability to accelerate your breakthroughs in regenerative medicine. Why Choose REPROCELL? ✅ Reprogramming & Licensing: Our own proprietary mRNA reprogramming technology ensures footprint-free iPSCs, eliminating concerns about vector retention or genomic integration, and provides a cost-effective licensing model. ✅ Rigorous QC Standards: Every iPSC line undergoes various assays, including genomic stability, quantitative and qualitative pluripotency marker analysis, and germ-layer differentiation among others to meet FDA, EMA, and PMDA standards. ✅ Custom Solutions: Whether you need clinical-grade iPSC Seed Clones or their matching Pilot Clones for research evaluation, we’ve got you covered! ✅ Global Expertise: Access to a worldwide network of human tissue samples with full donor consent for clinical and commercial use. 💡Contact our experts today: https://hubs.li/Q02_Wcv90 #iPSC #StemCellTherapy #RegenerativeMedicine #Innovation

The CHMP (Committee for Medicinal Products for Human Use) has adopted a positive opinion for Galderma's nemolizumab for the treatment of moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the EU. Nemolizumab targets IL-31, a key neuroimmune cytokine in the itch-signalling and inflammation pathways, will help patients by tackling one of the most problematic symptoms. This follows its U.S. FDA approval for PN earlier this year. At REPROCELL, we support innovations like these by offering human tissue assays for drug discovery studies. Our assays in fresh skin biopsies can measure critical cytokines like IL-31, providing disease-relevant human data to accelerate drug development. Read more information in the press release here: https://hubs.li/Q02_V6p00

🔬 Interested in clinical iPSC Clones or Services? At REPROCELL, as part of our iPSC services we can support your regenerative medicine project with our clinical-grade iPSCs. Hopefully our comprehensive FAQ page answers all your questions about our clinical iPSC production process. Key Topics Covered: • Donor Recruitment • Starting Primary Cell Types • RNA Reprogramming Technology • iPSC Manufacturing & Quality Control • Pricing & Royalties 🔗Click here to find out more: https://hubs.li/Q02_nbsY0 #stemcells #lifesciences #celltherapy

Inflammatory bowel disease (IBD) affects millions worldwide, with prevalence rising sharply. Despite advancements in treatments for Crohn’s disease and ulcerative colitis, the complexity of IBD presents ongoing challenges, including the persistent therapeutic ceiling limiting remission rates. At REPROCELL, we’re addressing this challenge head-on. By leveraging human-derived and bioengineered tissue models, we provide disease-relevant insights that mimic patient responses, enabling researchers to develop innovative, targeted therapies. From evaluating inflammation and fibrosis to testing combination therapies, our cutting-edge models are redefining preclinical research for IBD. Together, we can push past the therapeutic ceiling and improve outcomes for patients. Learn how we’re advancing IBD drug discovery in our new blog: https://hubs.li/Q02_nbnk0

It's beginning to look a lot like Christmas at REPROCELL! 🎄 In addition to wearing our festive jumpers, our team collected non-perishable food items to donate to the local food bank. It was a wonderful way to embrace the holiday season while giving back to the community. We wish you all a merry start to the holiday season. Stay tuned for more information about holiday closures and shipping information.

It's beginning to look a lot like Christmas at REPROCELL! 🎄 In addition to wearing our festive jumpers, our team collected non-perishable food items to donate to the local food bank. It was a wonderful way to embrace the holiday season while giving back to the community. We wish you all a merry start to the holiday season. Stay tuned for more information about holiday closures and shipping information.

Limbal stem-cell deficiency (LSCD) is a serious condition that can lead to vision loss and blindness by compromising corneal clarity and function, significantly impacting quality of life. LSCD affects up to 5 out of every 10,000 adults. For the first time, corneal epithelial cell sheets derived from iPSCs have been successfully used to treat LSCD. In this groundbreaking procedure, allogeneic human iPSC-derived epithelial cell sheets were transplanted onto affected eyes after the removal of fibrotic tissue enveloping the ocular surface. This innovative approach has shown remarkable safety and efficacy, as highlighted by the key findings from the clinical study conducted at Osaka University Hospital: ⬇️Key Study Outcomes: • Enhanced vision and reduced corneal opacity. • No serious adverse events (e.g., tumorigenesis or rejection) over 2 years. • Promising improvements in quality of life for patients with severe LSCD. This breakthrough highlights the transformative potential of iPSCs in regenerative medicine, paving the way for innovative treatments. At REPROCELL, we're proud to support such advancements through our clinical-grade iPSC services. 📰Link to the research article: https://hubs.li/Q02-Jblf0 👉Explore our clinical iPSC capabilities: https://hubs.li/Q02-JlxB0 #stemcells #immunotherapy #lifesciences #celltherapy #RegenerativeMedicine

Looking for a trusted partner in clinical biospecimen research? REPROCELL’s team of human tissue experts specializes in the precise handling, processing, and testing of clinical biospecimens. Our expertise ensures high-quality, human-relevant data to support your drug discovery and development programs. Let us help you drive innovation in your research. Discover how REPROCELL can make a difference: https://hubs.li/Q02_49YF0

Our recent webinar, "Modeling Cardiac Pathologies with TrueCardium™", is now available to stream! Prof.Jaya Krishnan shared insights into the creation of engineered iPSC-derived self-organized cardiac organoids (TrueCardium™ SCOs), which replicate the cell types of native human cardiac tissue. These cutting-edge organoids enable researchers to model the morphologic, physiologic, and functional impacts of various cardiac conditions—revolutionizing drug discovery and cardiotoxicity screening. Want to find out more? Check the webinar recording below: 🔴 Webinar: https://hubs.li/Q02-w19w0 #Webinar #CardiacOrganoids #DrugDiscovery #Cardiotoxicity #Innovation #LifeSciences